American Association for Cancer Research
TABLE_1.xls (9.5 kB)

TABLE 1 from A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors

Download (9.5 kB)
posted on 2023-08-24, 14:22 authored by Michael A. Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, Patricia LoRusso

Patient demographics and disposition



M8891 represents a novel class of reversible MetAP2 inhibitors and has demonstrated preclinical antitumor activity. This dose-escalation study assessed M8891 treatment for patients with advanced solid tumors. M8891 demonstrated favorable pharmacokinetics, tumoral target engagement, and a manageable safety profile, and thus represents a novel antitumor strategy warranting further clinical studies.